Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.

The research paper analyses the inflammatory responses of equine mesenchymal stem cells, both allogeneic and autologous types, in relation to the treatment of musculoskeletal injuries in horses. Results show that both types of stem cells exhibit equal response and effectiveness in treating horse injuries, debunking previous concerns on the safety and efficacy of allogeneic stem cells.

Introduction and Objective

• The research aimed to discern the immunological properties of equine bone marrow-derived mesenchymal stem cells (BMDMSCs), specifically comparing allogeneic (from a different individual of the same species) and autologous (from the same individual) BMDMSCs.
• The goal was to ascertain whether allogeneic BMDMSCs could be a viable alternative to autologous ones for treating equine musculoskeletal injuries.

Methodology

• Tested the cells’ inherent immunogenicity, that is, their ability to stimulate spontaneous expansion of equine lymphocytes (white blood cells).
• Analyzed the immunosuppressive activity of both allogeneic and autologous BMDMSCs by introducing them to activated lymphocytes and measuring the suppression of lymphocyte proliferation and IFNγ (a protein associated with immune response) production.
• Explored the mechanisms of how mesenchymal stem cells (MSCs) suppress lymphocyte function, focusing on the production of prostaglandin E (PGE), nitric oxide, transforming growth factor-beta, and indoleamine 2,3-dioxygenase.

Results and Findings

• The results showed that both autologous and allogeneic BMDMSCs induced mild but equivalent levels of spontaneous lymphocyte activation.
• Both allogeneic and autologous BMDMSCs also suppressed T cell proliferation and IFNγ production equivalently in vitro assays.
• The primary mechanism for BMDMSC suppression of T cells was found to be through PGE.

Conclusion and Implications

• It was concluded that allogeneic and autologous BMDMSCs have equivalent immunomodulatory properties, indicating that allogeneic BMDMSCs could be a safe and effective alternative for treating musculoskeletal injuries in horses.
• This suggests that allogeneic and autologous BMDMSCs have equal potential in modulating inflammatory processes related to acute or chronic musculoskeletal injuries in horses.